Stryker’s profits decreased 2.3% year-over-year in the fourth quarter, to $510 million, amid charges related to its recalled Rejuvenate or ABG II modular metal-on-metal neck hip stems, as well as expenses related to restructuring and acquisition costs.
Earnings per share were $1.34, down 2.9%. Excluding the charges, Stryker’s profits would have been up 14.1% to $1.78 per share, which falls in line with the expectations of analysts polled on Yahoo! Finance. Stryker’s stock was up slightly, to nearly $121.50 in early after-hours trading.
Get the full story on our sister site, MassDevice.